Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in L'hospitalet De Llobregat – page 28

978 clinical trials in L'hospitalet De Llobregat, Spain across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
L'hospitalet De Llobregat at a glance
978
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

978 trials in L'hospitalet De Llobregat

Open in trial search

Mantle cell lymphoma stage II+2

Recruiting

Study on CAR-T-cell Therapy with Rituximab and Ibrutinib for Patients with High-Risk Mantle Cell Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine
  • Sponsor:Klinikum Der Universitat Munchen AöR

Study on Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan for Adults with Prostate Cancer

Recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177Lu) Vipivotide Tetraxetan
  • Sponsor:Novartis Pharma AG

Malignant melanoma

Recruiting

Study on the Effectiveness and Safety of Lifileucel and Pembrolizumab for Patients with Untreated, Unresectable, or Metastatic Melanoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin
  • Sponsor:Iovance Biotherapeutics Inc.

Lymphangioma

Recruiting

Study on Alpelisib for Treating Lymphatic Malformations in Patients with PIK3CA Mutation

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Aortic stenosis

Recruiting

Study on Ticagrelor and Aspirin for Patients with Severe Aortic Stenosis After Heart Valve Replacement

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Fundacion Biomedica Galicia Sur

Hormone-refractory prostate cancer+1

Recruiting

Study of Gedatolisib and Darolutamide Combination Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Celcuity Inc.

Allogenic stem cell transplantation

Recruiting

Study on MaaT033 to Prevent Complications in Patients with Blood Cancer Undergoing Stem Cell Transplantation

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Faecal Microbiota, Pooled
  • Sponsor:Maat Pharma

Pneumonia

Recruiting

Study of Trimodulin for Adults Hospitalized with Severe Community-Acquired Pneumonia

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Trimodulin (Human Igm, Iga, Igg Solution)
  • Sponsor:Biotest GmbH & Co. KGaA

Malignant melanoma

Recruiting

Study to Compare Fianlimab and Cemiplimab Combination with Pembrolizumab in Patients with High-Risk Melanoma After Surgery

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

Recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

Glomerulonephritis rapidly progressive

Recruiting

Study on the Safety and Tolerability of Lixudebart and Rituximab for Patients with Rapidly Progressive Glomerulonephritis Due to ANCA-Associated Vasculitis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lixudebart
  • Sponsor:Alentis Therapeutics AG

Squamous cell carcinoma of head and neck

Recruiting

Study on the Safety and Effectiveness of VB10.16 and Pembrolizumab for Patients with HPV16-Positive Head and Neck Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Nykode Therapeutics ASA

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in L'hospitalet De Llobregat

What the registry says about research in the country

01 Infectious Disease Prevention

Innovative research focused on vaccine development targeting multiple infectious diseases, including studies on UTI prevention, yellow fever, and RSV protection in adults.

  • UTI Vaccine Safety & Efficacy
  • Yellow Fever Immunization
  • RSV Protection Studies

These trials aim to enhance vaccine effectiveness and improve public health outcomes through preventive measures.

02 Oncology Research

Comprehensive studies exploring new treatments for various types of advanced cancers, with particular focus on targeted therapies and novel drug combinations.

  • Colorectal Cancer Treatment
  • Gastric Cancer Therapies
  • Pancreatic Cancer Interventions

Advanced clinical research investigating innovative approaches to combat various forms of cancer.

03 Transplant Medicine

Groundbreaking research in kidney transplantation, focusing on preventing rejection and improving post-transplant outcomes.

  • Antibody-Mediated Rejection
  • Delayed Graft Function
  • Novel Immunosuppressive Approaches

Studies aimed at enhancing transplant success rates and patient recovery.

04 Autoimmune Conditions

Clinical investigations into treatments for various autoimmune disorders, including innovative therapies for inflammatory conditions.

  • Psoriatic Arthritis Treatment
  • Atopic Dermatitis Management
  • Myasthenia Gravis Therapy

Focused on developing targeted treatments to improve patient quality of life.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.